NCT07153861 Oral Mucosal Graft Versus Labial Graft in Female Urethroplasty
| NCT ID | NCT07153861 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tanta University |
| Condition | Oral Mucosal Graft |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-02-26 |
| Primary Completion | 2026-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-02-26 with a primary completion date of 2026-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to compare the oral versus labial graft in female urethroplasty in female urethral stricture.
Eligibility Criteria
Inclusion Criteria: * Female patients with urethral stricture. * Female patients with non-traumatic urethral stricture. Exclusion Criteria: * Female patients with traumatic urethral stricture. * Female patients with systemic contraindications of surgery like bleeding disorders.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07153861 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Oral Mucosal Graft. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07153861 currently recruiting?
Yes, NCT07153861 is actively recruiting participants. Contact the research team at Mohamed.elmaadawy@med.tanta.edu.eg for enrollment information.
Where is the NCT07153861 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT07153861 clinical trial?
NCT07153861 is sponsored by Tanta University. The trial plans to enroll 40 participants.